Assessment of Plasma Creatine Kinase as Biomarker for Levodopa-Induced Dyskinesia in Parkinson's Disease

J Neural Transm (Vienna). 2019 Jun;126(6):789-793. doi: 10.1007/s00702-019-02015-x. Epub 2019 May 16.


We tested in a translational approach the usefulness of plasma creatine kinase (CK) as an objective biomarker for levodopa-induced dyskinesia (LID). Plasma CK levels were measured in five dyskinetic parkinsonian non-human primates (NHP) and in ten PD patients with LID who participated in a treatment trial with simvastatin. Plasma CK levels were increased in dyskinetic NHP and correlated with LID severity while they were not affected by LID severity in PD patients.

Keywords: Biomarker; Creatine kinase; Levodopa-induced dyskinesia; Parkinson’s disease.

Publication types

  • Research Support, Non-U.S. Gov't